Log in
Enquire now
Metagenomi

Metagenomi

Metagenomi is a Gene-Edited Microbial Treatments.

OverviewStructured DataIssuesContributors

Contents

metagenomi.co
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Engineering
Engineering
Biomedical engineering
Biomedical engineering
Artificial Intelligence (AI)
Artificial Intelligence (AI)
Technology
Technology
Genomics
Genomics
‌
Genome editing
Biotechnology
Biotechnology
Location
United States
United States
California
California
San Francisco
San Francisco
Emeryville, California
Emeryville, California
Pitchbook URL
pitchbook.com/profiles...279522-64
Number of Employees (Ranges)
51 – 200
Email Address
info@metagenomi.co
Phone Number
+13126023335
Number of Employees
83
Investors
Novo Holdings A/S
Novo Holdings A/S
Catalio Capital Management
Catalio Capital Management
Bristol-Myers Squibb
Bristol-Myers Squibb
Total Funding Amount (USD)
175,000,000
Latest Funding Round Date
April 7, 2021
Competitors
Smpl Bio
Smpl Bio
Waabi
Waabi
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
1
Technologies Used
CRISPR
CRISPR
Country
United States
United States

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
75,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Metagenomi

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.